louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02000505: Comparison of the Quality of CPR by Lay Rescuers With and Without Feedback Devices
Official title: Comparison of the Quality of CPR by Lay Rescuers With and Without Telephone Instructions by a Simulated Rescue Coordination Center
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Arrest
Lead sponsor: University Hospital of Cologne
Sponsor class: OTHER
First posted: 2013-12-04
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison of various methods to improve the quality of CPR

Detailed description: Even for paramedics and emergency physicians, the resuscitation of patients with cardiac arrest remains a challenge. Previous studies have shown that the cardiac output varies widely even among professional helpers. This is especially due to some very different mean frequencies of cardiac compression wich vary from 60 to 160/min for paramedics. Aim of this study is to investigate whether the use of feedback-devices during cardiac-pulmonary resuscitation (CPR) can lead to an improvement of the cardiac output and may improve survival.

For this, we examine the impact of different feedback-methods on the frequence-variety on manikin by lay rescuers. Overall, we compare three different devices for feedback during CPR. The subjects for this study are lay rescuers who perform a 5 minute chest-compression-only CPR.

Eligibility criteria: Inclusion Criteria:

* lay rescuers
* \>18 years
* \<60 years

Exclusion Criteria:

* professional rescuers
* pregnancy

Primary outcomes:
measure: The average achieved cardiac output
timeFrame: after 5 minutes
Secondary outcomes:
measure: Constancy of the quality of chest-compressions
timeFrame: after 5 minutes
Other outcomes:
Locations:
city: Köln
country: Germany
facility: Uniklinik Köln
Study officials:
affiliation: University Hospital Cologne
name: Stefan Braunecker, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Cologne
name: Jochen Hinkelbein, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06767605: Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)
Official title: Registro Español de Enfermedades Hepáticas Colestásicas y Autoinmunes (ColHai)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hepatitis Autoimmune Disease
Primary Biliary Cholangitis (PBC)
Primary Sclerosing Cholangitis (PSC)
Cholestatic Genetic Diseases
Keywords: Cholestatic Genetic Diseases
Primary Sclerosing Cholangitis (PSC)
Hepatitis Autoimmune Disease
Primary Biliary Cholangitis (PBC)
PFIC tipo 1
PFIC tipo 2
PFIC tipo 3
PFIC tipo 4
BRIC tipo 1
BRIC tipo 2
Alagille syndrome
Rotor syndrome
Dubin Johnson syndrome
Genetic disease
Registry
cholestatic diseases
Lead sponsor: Asociación Española para el Estudio del Hígado
Sponsor class: OTHER
First posted: 2025-01-10
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a confirmed diagnosis for PBC, HAI, PSC or any genetic cholestasis

Brief summary: The purpose of the registry is to know the status of primary biliary colgantis, autoimmune hepatitis, primary sclerosing cholagitis and genetic cholestatic diseases in Spain.


Eligibility criteria: Inclusion Criteria:

* Patients with a confirmed diagnosis for PBC, HAI, PSC, genetic cholestatic disease

Exclusion Criteria:

* Refusal to sign the informed consent for the study

Primary outcomes:
measure: Prevalence and characteristics of autoimmune and cholestatic liver disease in Spain
timeFrame: 2025
Secondary outcomes:
measure: Development of liver-related events in autoimmune ahd cholestatic liver diseases
timeFrame: 2025
measure: Treatment of autoimmune and cholestatic liver diseases in Spain
timeFrame: 2016-2030
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clinic
Study officials:
affiliation: Asociación Española para el Estudio del Hígado
name: Maria Carlota Londoño Londoño
role: STUDY_DIRECTOR
References:
Clinical trial NCT00478998: Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin
Official title: Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Upper Tract Ureterolithiasis
Keywords: expulsion therapy
tamsulosin
ureterolithiasis
stents
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2007-05-25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see whether patients undergoing ESWL, for upper tract urinary stones between 1.5-2.0cm, may be treated by expulsion therapy(Tamsulosin) instead of inserting ureteral stents .


Eligibility criteria: Inclusion Criteria:

* Patients above 18 yrs of age.
* Single urolithiasis up to 2 cm.
* Kidney/ureters that haven't undergone previous ESWL or stent insertion.
* Normal renal function (creatinine below 100mmo1/1).
* Sterile urine culture.
* Normal CBC, blood electrolytes and coagulation studies.
* Radioopaque stones.

Exclusion Criteria:

* More than one stone per kidney unit.
* Patients receiving steroids, NSAIDS, calcium channel blockers or alpha blockers on a regular basis.
* Anatomical anomalies or uromechanical obstruction.
* Single kidney.
* Cystinuria.
* Soldiers or pregnant women.
* Patients under 18 year

Primary outcomes:
measure: stone status at 3 month .
measure: stone free
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Mordechai Duvdevani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06720298: CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors
Official title: CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Solid Tumor
Keywords: Solid Cancer
CD147
PET imaging
Lead sponsor: Peking University Cancer Hospital & Institute
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Malignant tumor patients or suspected patients

Brief summary: The objective of the study is to construct a noninvasive approach using 68Ga-DOTA-AP9 PET/CT to detect the CD147 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from CD147 targeting treatment.


Eligibility criteria: Inclusion Criteria:

1. Malignant melanoma, liver cancer, colon cancer, pancreatic cancer, breast cancer, gastric cancer, lung cancer, etc., confirmed by histopathology or cytology;
2. age ≥18 and ≤75 years old, male or female;
3. ECOG score 0 or 1;
4. expected survival time ≥6 months;
5. There was at least one measurable target lesion according to RECIST1.1 criteria, and biopsy could be performed within one month before and after PET scan, and the patient could provide 2-3 lesion tissue slides;
6. Women of childbearing age (15-49 years) must have had a negative pregnancy test within 7 days before starting testing; Women and men of childbearing potential must agree to use effective contraception to avoid pregnancy during the study and for 3 months after the examination;
7. patients recommended by clinicians to undergo PET/CT examination for tumor staging;
8. The subjects could fully understand and voluntarily participate in this experiment, and signed an informed consent.

Exclusion Criteria:

1. Pregnant or breastfeeding women, or women planning to become pregnant during the study or within three months after administration, as well as individuals donating sperm or oocytes.
2. Individuals known or suspected to be allergic to the investigational drug or any of its components.
3. Individuals with significantly abnormal liver or kidney function: serum total bilirubin (TBIL) \> 1.5 × 20 µmol/L, or aspartate aminotransferase (AST) \> 2.5 × 45 µmol/L, or alanine aminotransferase (ALT) \> 2.5 × 40 µmol/L, or serum creatinine \> 1.5 × 130 µmol/L.
4. Unable to cooperate in completing the PET scan, or suffering from claustrophobia or other conditions that prevent cooperation during the PET scan.
5. Other situations deemed inappropriate for participation in the trial by the investigator. Female patients who are pregnant or breastfeeding.

Primary outcomes:
measure: Standardized uptake value（SUV）
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT04783298: Can Methods From Computational Psychology be Used to Phenotype Individuals Most Likely to be Non-adherent to Fitness Goals?
Official title: Can Methods From Computational Psychology be Used to Phenotype Individuals Most Likely to be Non-adherent to Fitness Goals?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lifestyle, Sedentary
Lead sponsor: Dublin City University
Sponsor class: OTHER
First posted: 2021-03-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy individuals starting a new exercise regime.

Brief summary: This is a longitudinal study combining objective sensor data, with decision-making games and contextual personality traits to identify patterns in exercise decay. The data generated will be used to build computational models to predict digital personas, and help identify those individuals most likely to abandon exercise goals.

Detailed description: Interested individuals to be recruited on social media and invited to download the study app. The plain language statement and informed consent are embedded in the app. Once e-consent is obtained, individuals will share their Fitbit data and complete the following questionnaires; Type D Personality, Goal Setting, and Self-Efficacy questionnaire and a decision-making game based on the IGT. After a 6 month time period, they will be requested to retake the questionnaires and decision-making game.

Eligibility criteria: Inclusion Criteria:

* Healthy individuals who have a Fitbit

Exclusion Criteria:

* Individuals under the age of 18 years of age.

Primary outcomes:
measure: Change in physical activity measured by an increase in weekly steps measured by Fitbit.
timeFrame: Week 1 and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dublin
country: Ireland
facility: Dublin City University
Study officials:
References:
citation: McCarthy M, Zhang L, Monacelli G, Ward T. Using Methods From Computational Decision-making to Predict Nonadherence to Fitness Goals: Protocol for an Observational Study. JMIR Res Protoc. 2021 Nov 26;10(11):e29758. doi: 10.2196/29758.
Clinical trial NCT02356198: Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery
Official title: Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery: A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Conditions Requiring Colorectal Surgery
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2015-02-05
Enrollment: 209
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is prospective, randomized trial in which EXPAREL TAP block is compared to standard IT opioid administration, in relieving postoperative pain, decreasing length of stay, and use of narcotic medication.

Detailed description: Primary Objective To assess efficacy of EXPAREL TAP blocks in improving pain scores for 48 hours postoperatively, and in reducing total oral morphine equivalents (OME) use, compared to standard Intrathecal opioid administration (IT).

Secondary Objective Assess the length of stay (LOS), postoperative ileus (POI) incidence, and the use of intravenous patient controlled analgesia (PCA) in patients that had EXPAREL TAP blocs compared to IT.

Eligibility criteria: Inclusion Criteria:

* • All patients undergoing elective laparoscopic or open colorectal resections who are eligible for IT

  * Age \>18 years
  * BMI \<40
  * Ability to understand and read English

Exclusion Criteria:

* • Not able or unwilling to sign consent.

  * Currently pregnant or lactating.
  * Patients with chronic pain, requiring daily opiate use at time of surgery.
  * Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
  * Patients requiring emergent surgery.
  * Abdominoperineal resections
  * Any contraindications to neuraxial analgesia (coagulopathy, localized infection at the potential site of injection, pre-existing spinal canal pathology)
  * Patients with a diagnosis of inflammatory bowel disease

Primary outcomes:
measure: Mean Pain Score
timeFrame: First 48 hours post operative
measure: Total Morphine Milligram Equivalents Use (MME)
timeFrame: First 48 hours post operative
Secondary outcomes:
measure: Total Length of Hospital Stay
timeFrame: post-operative to discharge
measure: Number of Participants With Post-operative Ileus
timeFrame: 24 hours post-operatively
measure: Use of Intravenous Patient-controlled Analgesia
timeFrame: First 48 hours post-operative
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Dorin Colibaseanu, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Colibaseanu DT, Osagiede O, Merchea A, Ball CT, Bojaxhi E, Panchamia JK, Jacob AK, Kelley SR, Naessens JM, Larson DW. Randomized clinical trial of liposomal bupivacaine transverse abdominis plane block versus intrathecal analgesia in colorectal surgery. Br J Surg. 2019 May;106(6):692-699. doi: 10.1002/bjs.11141. Epub 2019 Mar 28.
Clinical trial NCT00195598: Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
Official title: Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Panic Disorders
Keywords: Panic Disorders
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-19
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.


Eligibility criteria: Inclusion Criteria:

* Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
* Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
* Provide a written informed consent

Exclusion Criteria:

* Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
* Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
* Psychopharmacologic drugs within 14 days of study day 1

Primary outcomes:
measure: To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.
Secondary outcomes:
measure: Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.
Other outcomes:
Locations:
city: Jundiai
country: Brazil
state: Sao Paulo
city: Santo Andre
country: Brazil
state: Sao Paulo
city: Sao Paulo
country: Brazil
city: Sao Paulo
country: Brazil
Study officials:
affiliation: Pfizer CT.gov Call Center
name: Trial Manager
role: STUDY_DIRECTOR
References:
Clinical trial NCT07016698: Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)
Official title: A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Peripheral Arterial Disease(PAD)
Keywords: Rotarex
PAD
Lead sponsor: C. R. Bard
Sponsor class: INDUSTRY
First posted: 2025-06-12
Enrollment: 600
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The XTRACT Registry is a prospective, single arm multicenter study on the use of on the Rotarex(TM) Rotational Excisional Atherectomy System.

Detailed description: The study will recruit approximately 600 subjects treated for PAD.

Eligibility criteria: Inclusion Criteria:

1. Subject or legally authorized representative provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the IRB for the site.
2. Subject is ≥22 years old at the time of signing the informed consent.
3. Subject must have a lesion(s) in their infra-inguinal peripheral arteries that can be treated with the RotarexTM Rotational Excisional Atherectomy System according to Instructions For Use (IFU).
4. Rutherford 2-5 for chronic limb ischemia and Rutherford I to IIb for acute limb ischemia.
5. Target lesion can be crossed intra-luminally by guidewire.
6. At least one patent native outflow artery to the foot, free from significant stenosis(≥50% stenosis as confirmed by angiography) (ChLI Cohort only, not applicable to ALI Cohort).

Exclusion Criteria:

1. Subject is unable or unwilling to comply with follow-up procedures and visits.
2. Subject has a target lesion in a vessel with less than 3 mm in diameter.
3. Subject is participating in another device or drug clinical trial that interferes with this protocol and confounds results.
4. Treatment plan includes use of a thrombectomy and/or atherectomy device other than RotarexTM Rotational Excisional Atherectomy System.
5. Life expectancy is below 1 year.
6. Pregnant, planning to become pregnant during the course of the study or nursing a child.

Primary outcomes:
measure: Procedural Success
timeFrame: Immediate Post Index Procedure
measure: Freedom from major complications
timeFrame: 30 days post index procedure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The Icahn School of Medicine, The Mount Sinai Health System
name: Prakash Krishnan, MD, FACC
role: PRINCIPAL_INVESTIGATOR
affiliation: NYU Langone Health
name: Todd L Berland, MD, FACS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03299998: Evaluation of Maxillary and Mandibulary Nerve Blocks on Morphine Consumption
Official title: Evaluation of Maxillary and Mandibulary Nerve Blocks on Morphine Consumption in Double-jaw Surgery, a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dento Facial Dysmorphism
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-10-03
Enrollment: 92
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and female who underwent double jaw surgery

Brief summary: Background and Objectives: Double-jaw surgery is one of the most painful oral surgery, requiring multimodal analgesia including controlled morphine pump and its secondary effects. The aim of this study was to evaluate the effectiveness of face block (mandibulary and maxillary block analgesia) on the first 24 hours on morphine consumption in patients admitted for double jaw surgery.

Detailed description: Methods: Patients undergoing double-jaw surgery between January 2015 and May 2017 were enrolled. Patients were separated into 2 groups: patients receiving maxillary-mandibulary nerve block and those no receiving it. The primary endpoint was the morphine consumption within 24 hours post-surgery. Secondary endpoints were the intra-operative remifentanil consumption, incidence of postoperative nausea and vomiting at 24 hours, morphine consumption in recovery room, length of stay in hospital.

Eligibility criteria: Inclusion Criteria:

- Male and female who underwent double jaw surgery

Exclusion Criteria:

* opposition to the study
* an additional surgical procedure
* preoperative consumption of morphine or derived from morphine
* perioperative N20

Primary outcomes:
measure: Cumulative morphine consumption within 24 hours post-surgery
timeFrame: 24 hours
Secondary outcomes:
measure: Peroperative remifentanil consumption
timeFrame: End of surgery (2 hours in average)
measure: Cumulative morphine consumption within 12 hours post-surgery
timeFrame: 12 hours
measure: Cumulative morphine consumption within 48 hours post-surgery
timeFrame: 48 hours
measure: Hospital length of stay
timeFrame: Up to hospital discharge (5 days in average)
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
References: